The objective of this Notice of Funding Opportunity (NOFO) is to invite new and renewal applications for the Rare Diseases Clinical Research Consortia (RDCRC) that comprise the Rare Diseases Clinical Research Network (RDCRN). The RDCRCs are intended to advance and improve diagnosis, management, and treatment of numerous, diverse rare diseases through highly collaborative, multi-site, patient-centric, translational, and clinical research. Special emphasis will be placed on the early and timely identification of individuals with rare diseases and clinical trial readiness.
Deadlines:
- Letter of Intent Due Date(s): 30 days prior to the application due date
- Application Due Date: August 19, 2024
PAR-24-206 Expiration Date New Date August 20, 2024 (Original Date: August 14, 2024) per issuance of NOT-TR-24-027
The RDCRC PD/PI(s) should have documented experience in conducting research on a disorder that qualifies as a rare disease (within the definition of this NOFO) and must have demonstrated experience in managing large multi-component clinical research programs. The RDCRC PD(s)/PI(s) cannot serve as the PD/PI of a project in another active RDCRC at the time of award, however collaborations among RDCRCs are encouraged. The minimum effort of the PD(s)/PI(s) across RDCRC projects and/or cores should be at least 2.0 person months per year. If there are multiple PDs/PIs each individual must meet the minimum requirement.
Applicants may request up to $1 million in direct costs/year. All costs must be well justified in accordance with the activity proposed.
Applicants may request up to 5 years of support.